Posttranslational Modifications of PPAR‐γ: Fine‐tuning the Metabolic Master Regulator
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family of ligand-dependent transcription factors, which comprise a subgroup of three closely homologous genes, PPAR-α (NR1C1), PPAR-β/δ (NR1C2), and PPAR-γ (NR1C3) (refs. 1,2). All PPARs bind to PPAR responsive elements in the promoter regions of target genes as obligate heterodimers with retinoic acid X receptors. Similar to other nuclear receptors, PPARs consist of distinct functional domains including an N-terminal transactivation domain (AF1), a highly conserved DNA-binding domain (DBD), and a C-terminal ligand-binding domain (LBD) that contains a ligand-dependent transactivation function (AF2; Figure 1a). Ligand binding stabilizes the active conformation of the LBD, thereby serving as a "molecular switch" between activation and repression functions of the receptor (3). On the promoters of some target genes, unliganded PPARs recruit corepressors such as N-CoR and SMRT, which are part of multiprotein complexes containing histone deacetylase activity that repress gene transcription (4). Upon ligand binding, these corepressor complexes are exchanged for activating co-activator complexes, including the SRC1/CBP and TRAP/DRIP/ARC complexes (5). Besides ligand-mediated regulation, the transcriptional activity of nuclear receptors can also be regulated via the ligand-independent AF1 domain. In common with other NRs (6), the AF1 domains of the different PPAR isotypes probably lack a stable secondary structure in aqueous solution, only to adopt a stable conformation upon interaction with other proteins. Posttranslational modifications of PPAR-γ. (a) Schematic representation of the PPAR-γ2 protein. Indicated are the N-terminal activation function 1 (AF1), the DNA-binding domain (DBD), and the C-terminal activation function 2 (AF2), as well as the unique phoshorylation site at position serine 112 and the SUMO sites at position lysine 107 and lysine 395. (b) The sumoyl-phospho switch motif or phosphorylation-dependent sumoylation motif in PPAR-γ1/2 is conserved between species ranging from fish to man. The nuclear receptors ERRα, ERRβ, and ERRγ harbor a similar motif. (c) Phosphorylation of S112 of PPAR-γ by ERK1/2 kinases upon growth factor or prostaglandin PGF2α treatment, or by p38/JNKs after UV or stress results in the inhibition of the adipogenic gene program. The adapter protein Dok1 can modulate MAPK activation. (d) Phosphorylation of S112 of PPAR-γ by the kinases cdk7 (as part of the TFIIH complex) or cdk9 (as part of the P-TEFb complex) results in the stimulation of the adipogenic gene program. ERK, extracellular signal-regulated kinase; ERR, estrogen-related receptor; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; PPAR, peroxisome proliferator-activated receptor; P-TEFb, positive transcription elongation factor b; SUMO, small ubiquitin-like modifier; TFIIH, general transcription factor II H. Although all PPAR nuclear receptors play a part in lipid homeostasis and energy metabolism, the different PPAR proteins exhibit different physiological roles due to (i) distinct expression patterns, (ii) specific activation by different ligands, and (iii) intrinsic functional differences between the different isotype proteins. Alternative splicing and differential promoter usage results in two PPAR-γ isoforms, PPAR-γ1 and PPAR-γ2, with the latter harboring a 30-residue extension at its N-terminus (1,2). PPAR-γ1 is expressed in several tissues, including the lower intestine, macrophages, and white adipose tissue (WAT), whereas PPAR-γ2 expression is almost exclusively restricted to WAT. The endogenous ligands for PPAR-γ are not firmly established, although some natural compounds, such as polyunsaturated fatty acids, prostaglandin J2 derivatives (15-deoxy-δ12,14-PGJ2), and nitro-oleic acid, have been shown to be able to activate PPAR-γ (7,8). Synthetic PPAR-γ agonists include the thiazolidinediones (TZDs), which ameliorate insulin resistance and lower blood glucose levels in patients with type 2 diabetes (9). A huge amount of data indicates that PPAR-γ is one of the key players in the differentiation of fibroblast-like mesenchymal stem cells into adipocytes, a process known as adipogenesis. For example, PPAR-γ+/– mice lack most adipose tissue (10,11,12), whereas in vitro differentiation of fibroblasts into mature adipocytes can be induced by the introduction of PPAR-γ (13). In addition, PPAR-γ is also essential for the maintenance of adipose tissue, because conditional knock-out of the Pparg gene resulted in reduced in vivo survival of mature adipocytes (14). Besides its role in adipocyte differentiation and maintenance, PPAR-γ directly regulates the expression of a number of genes involved in net lipid partitioning into mature adipocytes, underscoring the importance of PPAR-γ in glucose and lipid homeostasis. Compelling genetic evidence for this view comes from human familial partial lipodystrophy subtype 3 (MI
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Kintscher, U., Hartge, M., Hess, K., Foryst-Ludwig, A., Clemenz, M., Wabitsch, M., Fischer-Posovszky, P., Barth, T. F. E., Dragun, D., Skurk, T., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.165100 · Cited by 692
Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.022 · Cited by 561 · cited 1×
“A similar mechanism was recently reported for the transrepression of NFκB target genes by the nuclear receptors LXRα and LXRβ, although in this case SUMO-2 or SUMO-3 and not SUMO-1 was conjugated to the receptor (48).”
BackgroundFatty Acid Transduction of Nitric Oxide Signaling
Baker, P. R. S., Lin, Y., Schopfer, F. J., Woodcock, S. R., Groeger, A. L., Batthyany, C., Sweeney, S., Long, M. H., Iles, K. E., Baker, L. M. S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504212200 · Cited by 358 · cited 1×
“The endogenous ligands for PPAR-γ are not firmly established, although some natural compounds, such as polyunsaturated fatty acids, prostaglandin J2 derivatives (15-deoxy-δ12,14-PGJ2), and nitro-oleic acid, have been shown to be able to activate PPAR-γ (7,8).”
Background
Cited by
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action
Hernandez-Quiles, M., Broekema, M. F., & Kalkhoven, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624112 · Cited by 433
Self-citationBaskaran, P., Krishnan, V., Ren, J., & Thyagarajan, B. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13514 · Cited by 325
Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2017-0019 · Cited by 256
Yepuru, M., Eswaraka, J., Kearbey, J. D., Barrett, C. M., Raghow, S., Veverka, K. A., Miller, D. D., Dalton, J. T., & Narayanan, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.147850 · Cited by 125
Metadata
- Authors
- van Beekum, O., Fleskens, V., & Kalkhoven, E.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2009-02
- Volume
- 17
- Issue
- 2
- Pages
- 213-219
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2007381747
- Cited by
- 146
- References
- 4
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Posttranslational Modifications of PPAR‐γ: Fine‐tuning the Metabolic Master Regulator. https://app.cochat.ai/papers/10.1038/oby.2008.473
- The paper
- van Beekum, O., Fleskens, V., & Kalkhoven, E. (2009). Posttranslational Modifications of PPAR‐γ: Fine‐tuning the Metabolic Master Regulator. Obesity. https://doi.org/10.1038/oby.2008.473
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.